Background: Inherited BRCA1 and BRCA2 (BRCA1/2) mutations confer elevated breast cancer
In order to resolve whether BARD1 is a modifier of BRCA1 and BRCA2-associated breast cancer risk, we undertook a large study to comprehensively assess the association of BARD1
Cys557Ser as well as haplotypic variation with cancer risk in BRCA1 and BRCA2 carriers.
Materials and Methods

Study Sample
The design for this study has been described in detail previously (13) . Briefly, eligible participants included adult women with documented disease-associated inherited mutations in BRCA1 or BRCA2. Mutations were included in the analysis if they were pathogenic according to generally recognized criteria (14, 15 BRCA2 mutation carriers participating in the MAGIC consortium was used to further explore the relationship between BARD1 haplotypes and breast cancer risk. Recruitment and genetic studies were approved by relevant ethics committees at all sites, and informed consent was obtained from each participant.
Laboratory Methods
For analysis of the BARD1 Cys557Ser SNP, existing genotype data from BRCA1 and BRCA2 mutation carriers was requested from members of the CIMBA consortium. The primary methods Sequence data were analyzed using the Staden preGap4 and Gap4 programs. Samples from IHCC were typed by PCR-RFLP (10) . SNP quality control measures included >95% success rate, Hardy-Weinberg Equilibrium P>0.005, In addition, concordance of more than 98% for duplicate samples was required for studies that had included 2% duplicated samples for quality control purposes (all studies undergoing Sequenom iplex for BARD1 Cys557Ser, and all samples included in the haplotype sub-study).
For studies of BARD1 haplotypic variation, 11 haplotype tag SNPs were identified and assayed at the University of Pennsylvania as previously described (16) . The rs IDs were as follows: rs6712055, rs16852689, rs280621, rs13021937, rs13423596, rs10190829, rs6751923, rs4234006, rs28997576, rs3768708, rs1374230.
Statistical Methods
To assess the relationship between BARD1 SNPs and breast cancer risk, proportional hazards models were used as previously described (16, 17) . Briefly, participants were followed from the time of genetic testing or study ascertainment until the first diagnosis of breast cancer (the primary event in this analysis) or were censored at ovarian cancer. Participants who developed breast cancer were censored at bilateral prophylactic mastectomy if it occurred more than a year prior to the cancer diagnosis. This is to avoid censoring at bilateral mastectomies at which occult tumors were detected, but ages are rounded. The remaining participants were censored at the age at last observation. To address the problem of non-random sampling of mutation carriers with respect to the disease phenotype, analyses used the weighted Cox regression approach (17) , where affected and unaffected individuals were differentially weighted such that observed breast (18) . Analyses assessing the association of the BARD1 Cys557Ser SNP combined heterozygote and homozygote variant carriers under a dominant model due to the rare frequency of this variant. Analyses were assessed separately for BRCA1 and BRCA2 mutation carriers, adjusted for Study group, ethnicity (non-Jewish Caucasian, Jewish or other), and year of birth cohort (decade of birth, categorized as <1940, 1940-1949, 1950-1959, 1960-1969, 1970-1989 ). There were 3047 breast cancer events out of 5546 total for BRCA1 (55%) and 1578 breast cancer events out of 2865 total for BRCA2 (55%) for the Cys557Ser censored analysis datasets. The remainder were censored for analysis. Secondary analyses adjusted for prophylactic oophorectomy, or assessed risk for the subset of carriers with mutations determined to result in unstable transcripts/proteins (class 1 loss of function mutations). R version 2.7.0 was used for single SNP statistical analyses.
To investigate haplotype effects, the Estimation-maximization algorithm (19, 20) was used to estimate haplotype frequencies as implemented in R version 2.1.1 subroutine haplo.em(21) as previously described (16) . In this analysis, we included 607 breast cancer cases and 863 censored observations for BRCA1, and 813 breast cancer cases and 423 controls for BRCA2.
Results and Discussion
The frequency of the Cys557Ser SNP in the combined dataset (Table 1) For the haplotype analysis (Table 2) , we also observed no overall effect of variation at -1.85) or BRCA2 (HR=0.69, 95%CI: 0.28-1.72) . Indeed, neither of these estimates was associated with increased risk of breast cancer as previously reported.
The data presented here do not provide evidence that neither the BARD1 Cys557Ser SNP nor additional haplotypic variability not captured by Cys557Ser is associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Our sample size had>99% power to detect the effect size reported by Stacey et al. (6) of OR=3.1. The study had >80% power to detect risk ratios of 0.89 (or 1.13) for BRCA1 carriers and 0.86 (or 1.17) for BRCA2 carriers. The upper 95% confidence limits on the rate ratio in our analysis exclude any substantial risk.
Conclusion
Our study found no evidence to support substantial associations of BARD1 variation with increased breast cancer risk in BRCA1 and BRCA2 carriers. 
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